Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling
Yanli Hou, Bowen Sun, Wenxue Liu, Bo Yu, Qiqi Shi, Fei Luo, Yongrui Bai, Haizhong Feng
Abstract
Our data demonstrate AEBP1 as a new druggable target in GBM and ACT001 as a potential therapeutic option for improving the clinical treatment of GBM in combination with SHP099.
Topics & Concepts
ParthenolidePI3K/AKT/mTOR pathwayProtein kinase BGliomaStem cellChemistryCancer researchSignal transductionCell biologyPharmacologyBiologyBiochemistryApoptosisUbiquitin and proteasome pathwaysHistone Deacetylase Inhibitors ResearchCancer, Hypoxia, and Metabolism